Compare AMRX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMRX | CNS |
|---|---|---|
| Founded | 2002 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.2B |
| IPO Year | 2018 | 2004 |
| Metric | AMRX | CNS |
|---|---|---|
| Price | $13.20 | $64.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $14.75 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 1.6M | 246.5K |
| Earning Date | 05-15-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 4.13% |
| EPS Growth | ★ 157.89 | N/A |
| EPS | 0.22 | ★ 2.97 |
| Revenue | N/A | ★ $427,536,000.00 |
| Revenue This Year | $6.40 | $7.83 |
| Revenue Next Year | $6.54 | $11.02 |
| P/E Ratio | $60.25 | ★ $21.89 |
| Revenue Growth | N/A | ★ 4.07 |
| 52 Week Low | $6.69 | $58.39 |
| 52 Week High | $15.42 | $85.86 |
| Indicator | AMRX | CNS |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 42.60 |
| Support Level | $12.50 | $63.76 |
| Resistance Level | $13.49 | $64.43 |
| Average True Range (ATR) | 0.42 | 2.28 |
| MACD | -0.21 | -0.25 |
| Stochastic Oscillator | 14.89 | 42.05 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.